Ashita J Tolwani

US Patent:

8147698, Apr 3, 2012

Filed:

Jan 20, 2011

Appl. No.:

13/010770

Inventors:

Ashita Tolwani - Birmingham AL, US
Rajesh Speer - Birmingham AL, US
Brenda Stofan - Birmingham AL, US

Assignee:

The UAB Research Foundation - Birmingham AL

International Classification:

B01D 61/24
A61K 33/14
A61K 33/00
A61K 31/19
A61M 1/14

US Classification:

210647, 210645, 210646, 604 401, 604 501, 424680, 514557, 514575

Abstract:

The present disclosure describes novel standardized citrate replacement fluid solutions and a standardized dialysate solution for use with CRRT methods. The standardized citrate replacement fluid solutions and standardized dialysate solutions do not require modification based on the clinical status of the individual patients. The use of the standardized solutions described herein offers significant advantages over the prior art solutions used in CRRT. The present disclosure describes superior metabolic and electrolyte control and significantly increased dialyzer patency in: (a) 24 intensive care unit (ICU) patients with ARF using a 0. 67% trisodium citrate replacement fluid solution, and (b) 32 ICU patients with ARF using a 0. 5% trisodium citrate replacement fluid solution. Both groups were treated with Bicarbonate-25 dialysate and achieved effluent rates of 35 mL/kg/hr.

US Patent:

20070110829, May 17, 2007

Filed:

Nov 14, 2005

Appl. No.:

11/273290

Inventors:

Ashita Tolwani - Birmingham AL, US
Rajesh Speer - Birmingham AL, US
Brenda Stofan - Homewood AL, US

International Classification:

A61K 33/14
A61K 31/19
A61K 33/00

US Classification:

424680000, 424717000, 514575000, 514557000

Abstract:

The present disclosure describes novel standardized citrate replacement fluid solutions and a standardized dialysate solution for use with CRRT methods. The standardized citrate replacement fluid solutions and standardized dialysate solutions do not require modification based on the clinical status of the individual patients. The use of the standardized solutions described herein offers significant advantages over the prior art solutions used in CRRT. The present disclosure describes superior metabolic and electrolyte control and significantly increased dialyzer patency in: (a) 24 intensive care unit (ICU) patients with ARF using a 0.67% trisodium citrate replacement fluid solution, and (b) 32 ICU patients with ARF using a 0.5% trisodium citrate replacement fluid solution. Both groups were treated with Bicarbonate-25 dialysate and achieved effluent rates of 35 mL/kg/hr.